Pharmacoeconomic analysis of rituximab and belimumab therapy in patients with systemic lupus erythematosus

The progressive course of systemic lupus erythematosus (SLE) with high activity and severe internal organs involvement requires the prescription of expensive biologic disease-modifying antirheumatic drugs (bDMARDs), rituximab (RTM) and belimumab (BLM), whose comparative clinical and economic efficac...

Full description

Bibliographic Details

Published in:	Современная ревматология
Main Authors:	D. A. Gerasimova, V. A. Gontarenko, E. V. Gerasimova, O. V. Zakharova, L. А. Lobuteva, T. V. Popkova, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-10-01
Subjects:	clinical and economic analysis systemic lupus erythematosus belimumab rituximab cost-effectiveness analysis
Online Access:	https://mrj.ima-press.net/mrj/article/view/1637